Predicting Response to Intravesical Immunotherapy with BCG

Presented By:
Ashish Kamat, MD, MBBS - Professor of Urology and Director of Urologic Oncology Fellowship, M.D. Anderson Cancer Center
Speaker Biography:
Dr Ashish M. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at M.D. Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr Kamat's expertise is in multidisciplinary management of urologic cancers with an emphasis bladder and prostate cancer, organ sparing therapies, minimally invasive techniques, and orthotopic bladder substitution (neobladder). While he is a busy surgeon, he maintains an active research portfolio to improve the care of patients. Dr Kamat's efforts are directed towards identifying predictors of response to therapy - especially immunotherapy - as a first step towards personalized cancer therapeutics.
Webinar:
Predicting Response to Intravesical Immunotherapy with BCG
Webinar Abstract:
Dr. Kamat will present his clinical experience using molecular markers, in addition to the standard of care, to examine patient outcomes in the BCG response monitoring scenario.
Learning Objectives:
-Review of Bladder Cancer case studies to understand the use of BCG in bladder cancer subtypes
-Understand BCG tolerance, patient response, and use of UroVysion
Earn PACE Credits:
1. Make sure you’re a registered member of LabRoots (www.labroots.com/ms/webinar/p...)
2. Watch the webinar on KZbin or on the LabRoots Website (www.labroots.com/ms/webinar/p...)
3. Click Here to get your PACE credits (Expiration date - June 05, 2020 09:00 AM): www.labroots.com/credit/pace-...
LabRoots on Social:
Facebook: / labrootsinc
Twitter: / labroots
LinkedIn: / labroots
Instagram: / labrootsinc
Pinterest: / labroots
SnapChat: labroots_inc